article · Ain Shams Medical Journal
Background: Prostate cancer is regarded as the second cause of_ cancer-related mortality in males globally. Radiation therapy and/or radical_ prostatectomy are effective forms of treatment. Nevertheless, between 15. and 53% of the treated individuals experienced a biochemical recurrence within ten years.Aim of the Work: To evaluate 18F-PSMA PET/CT imaging's diagnostic efficacy in the biochemical_ prostatic cancer _recurrence after_ radical prostatectomy, hormonal. therapy,_ and radiotherapy.Patients and Methods: The_ study is _conducted in the radiology department at. a tertiary hospital. Twenty-six. patients with treated cancer prostate cancer were referred to. our study who had their PSA levels rising to assess the risk of. local. recurrence.Results: Twenty out of twenty-six patients revealed_ a positive study suggestive of recurrent prostate carcinoma 18F_ PSMA PET/CT with no- definite positive_ scans detected at PSA level > 0.2 ng/ml. Patients were _ divided into. 3 groups according to their PSA level _distribution by the 25th and_ 5th percentiles. Statistically strong _ positive _correlation between_ the PSA level and - number of local or distant recurrences with p-value (_<0.001). However, there was no strong correlation between PSA level and recurrence in osseous regions with p-value (_>0.05).Conclusion: Our results verified the utility of 18F-PSMA-PET/CT in identifying prostatic cancerous biochemical recurrence at various PSA levels. An elevated PSA increases the likelihood of a pathogenic 18F-PSMA PET_CT among patients.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/asmj.2024.250751.1185
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.